Cutaneous Melanoma
Melanoma is a common cancer in the US. Treatment for stage IA-IIA melanoma is surgical resection. Anti-PD-1 immunotherapy after surgical excision improves recurrence-free survival in stages IIB-C melanoma. For stage III melanoma, anti-PD-1 immunotherapy or BRAF + MEK inhibitor therapy decreases risk of melanoma recurrence. First-line therapy for metastatic melanoma is dual checkpoint blockade with ipilimumab and nivolumab.
Authors
- John M. Kirkwood (ORCID: https://orcid.org/0000-0002-3570-4476)
- Urvashi Mitbander Joshi
- Mohammed Kashani–Sabet (ORCID: https://orcid.org/0000-0001-5265-0011)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- California Pacific Medical Center (US)
- UPMC Hillman Cancer Center (US)
- University of Pittsburgh Medical Center (US)
Publication Details
- Journal
- JAMA
- Published
- 2025-08-25
- DOI
- https://doi.org/10.1001/jama.2025.13074
- Citations
- 13
- Primary Topic
- Cutaneous Melanoma Detection and Management
- Type
- article
- Field-Weighted Citation Impact
- 13.59